The Canadian Diabetes Association has become Diabetes Canada*
To be used for vascular protection, even if the baseline blood pressure or LDL-C is at target
Does the patient have clinical cardiovascular disease?
Does the patient have type 2 diabetes?
Is the patient's A1C above target?
Does the patient have clinical microvascular disease?
What is the patient's age?
How long has the patient been diagnosed with diabetes?
Does the patient have at least one of the following risk factor for cardiovascular disease?
Potentially embryopathic – discontinue prior to conception. Try to achieve targets in Canadian Cardiovascular Society guidelines, prescribe up to maximally tolerated and approved dose.
Potentially embryopathic – discontinue prior to conception (used to treat hypertension) or upon detection of pregnancy (used to treat CKD). Caution if hypotensive. Prescribe at doses with demonstrated vascular protection.
No safety data – discontinue prior to conception. Prescribe at doses with demonstrated vascular protection. Go to Pharmacotherapy for Type 2 Diabetes for more details.
Next step: download and complete a Prescription for Cardiovascular Protection with Diabetes
Prescription for Cardiovascular Protection with Diabetes:Download PDF
Risk Assessment Algorithm:Download PDF
Additional Resources: Canadian Cardiovascular Society (CCS) Guideline Resources
*The Canadian Diabetes Association is the registered owner of the name Diabetes Canada. All content on guidelines.diabetes.ca, CPG Apps and in our online store remains exactly the same. For questions, contact communications@diabetes.ca.